Region: Global
Category: Pharmaceuticals

Global Pharmaceuticals

(21,440 reports matching your criteria)
  • Food Grade Glycerin

    ... at a CAGR of 5.7% over the analysis period 2024-2030. Personal Care Application, one of the segments analyzed in the report, is expected to record a 6.5% CAGR and reach US$937.1 Million by the end ... Read More

  • Gaucher Disease Treatment

    ... at a CAGR of 3.8% over the analysis period 2024-2030. Enzyme Replacement Therapy, one of the segments analyzed in the report, is expected to record a 3.4% CAGR and reach US$1.7 Billion by the end ... Read More

  • Glucose, Dextrose, and Maltodextrin

    ... 2030, growing at a CAGR of 5.8% over the analysis period 2024-2030. Glucose, one of the segments analyzed in the report, is expected to record a 5.9% CAGR and reach US$32.3 Billion by the end ... Read More

  • Glycerol

    ... 3.6% over the analysis period 2024-2030. Personal Care & Cosmetics End-Use, one of the segments analyzed in the report, is expected to record a 4.0% CAGR and reach US$1.4 Billion by the end of the ... Read More

  • GMO Testing

    ... CAGR of 7.0% over the analysis period 2024-2030. Stacked Trait Testing, one of the segments analyzed in the report, is expected to record a 7.6% CAGR and reach US$2.6 Billion by the end of the ... Read More

  • Botanical Supplements

    ... CAGR of 8.0% over the analysis period 2024-2030. Spices, one of the segments analyzed in the report, is expected to record a 8.8% CAGR and reach US$22.3 Billion by the end of the analysis period. ... Read More

  • Heavy-Duty Pumps

    ... CAGR of 4.8% over the analysis period 2024-2030. Centrifugal Pumps, one of the segments analyzed in the report, is expected to record a 5.0% CAGR and reach US$19.1 Billion by the end of the analysis ... Read More

  • Herbal Supplements and Remedies

    ... 2030, growing at a CAGR of 8.7% over the analysis period 2024-2030. Multi-Herb Supplements and Remedies, one of the segments analyzed in the report, is expected to record a 9.4% CAGR and reach US$94.2 Billion ... Read More

  • Organic Foods and Beverages

    ... 2030, growing at a CAGR of 14.2% over the analysis period 2024-2030. Organic Fruits & Vegetables, one of the segments analyzed in the report, is expected to record a 15.5% CAGR and reach US$258.8 Billion ... Read More

  • Radiation Therapy Equipment

    ... at a CAGR of 6.6% over the analysis period 2024-2030. External Beam Radiation Therapy, one of the segments analyzed in the report, is expected to record a 6.8% CAGR and reach US$8.1 Billion by the ... Read More

  • Sepsis Therapeutics

    ... CAGR of 6.3% over the analysis period 2024-2030. Cephalosporin, one of the segments analyzed in the report, is expected to record a 6.6% CAGR and reach US$3.1 Billion by the end of the analysis period. ... Read More

  • Synthetic Biology

    ... CAGR of 27.9% over the analysis period 2024-2030. Oligonucleotides & Synthetic DNA Tool, one of the segments analyzed in the report, is expected to record a 29.1% CAGR and reach US$39.5 Billion by the end ... Read More

  • Dental Infection Control Products

    ... 2030, growing at a CAGR of 6.9% over the analysis period 2024-2030. Dental Infection Control Consumables, one of the segments analyzed in the report, is expected to record a 7.7% CAGR and reach US$1.3 Billion ... Read More

  • Automated Storage and Retrieval Systems (ASRS)

    ... reach US$13.4 Billion by 2030, growing at a CAGR of 7.1% over the analysis period 2024-2030. Unit Load ASRS, one of the segments analyzed in the report, is expected to record a 6.6% CAGR and ... Read More

  • Computer Aided Engineering (CAE)

    ... 2030, growing at a CAGR of 11.1% over the analysis period 2024-2030. Finite Element Analysis (FEA), one of the segments analyzed in the report, is expected to record a 11.6% CAGR and reach US$12.6 Billion ... Read More

  • Ginseng

    ... 10.2% over the analysis period 2024-2030. Asian Ginseng, one of the segments analyzed in the report, is expected to record a 10.0% CAGR and reach US$11.2 Billion by the end of the analysis period. Growth ... Read More

  • Interventional Radiology Systems

    ... at a CAGR of 7.1% over the analysis period 2024-2030. MRI Systems, one of the segments analyzed in the report, is expected to record a 8.1% CAGR and reach US$12.7 Billion by the end of ... Read More

  • OTT Devices and Services

    ... 2030, growing at a CAGR of 17.9% over the analysis period 2024-2030. Video Content, one of the segments analyzed in the report, is expected to record a 18.3% CAGR and reach US$252.9 Billion by the ... Read More

  • COVID-19 Testing

    ... CAGR of -15.7% over the analysis period 2024-2030. RT-PCR Assay Kits, one of the segments analyzed in the report, is expected to record a -16.5% CAGR and reach US$3.9 Billion by the end of the ... Read More

  • Ophthalmic Lasers

    ... CAGR of 5.0% over the analysis period 2024-2030. Femtosecond Lasers, one of the segments analyzed in the report, is expected to record a 5.8% CAGR and reach US$757.4 Million by the end of the analysis ... Read More

  • Antidepressants

    ... 2.5% over the analysis period 2024-2030. Major Depressive Disorder, one of the segments analyzed in the report, is expected to record a 2.2% CAGR and reach US$7.0 Billion by the end of the analysis period. ... Read More

  • Ophthalmic Pharmaceutical Drugs

    ... at a CAGR of 3.6% over the analysis period 2024-2030. Anti-VEGF Agents, one of the segments analyzed in the report, is expected to record a 4.4% CAGR and reach US$34.3 Billion by the end of ... Read More

  • Insulin Pumps

    ... CAGR of 7.0% over the analysis period 2024-2030. Tethered Pumps, one of the segments analyzed in the report, is expected to record a 6.6% CAGR and reach US$15.0 Billion by the end of the analysis ... Read More

  • Intelligent Pumps

    ... CAGR of 6.1% over the analysis period 2024-2030. Centrifugal Pumps, one of the segments analyzed in the report, is expected to record a 6.6% CAGR and reach US$1.5 Billion by the end of the analysis ... Read More

  • Intrauterine Devices

    ... CAGR of 3.8% over the analysis period 2024-2030. Hormonal Progestogen-Releasing IUD, one of the segments analyzed in the report, is expected to record a 3.4% CAGR and reach US$3.4 Billion by the end of the ... Read More

Cookie Settings